AN2 Therapeutics
ANTX
37 hedge funds and large institutions have $9.88M invested in AN2 Therapeutics in 2025 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
6% more funds holding
Funds holding: 35 → 37 (+2)
1.33% more ownership
Funds ownership: 30.29% → 31.62% (+1.3%)
6% less capital invested
Capital invested by funds: $10.5M → $9.88M (-$633K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$170K |
| 2 |
Millennium Management
New York
|
+$112K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$108K |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$74.5K |
| 5 |
AC
Almitas Capital
Santa Monica,
California
|
+$59.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$54.9K |
| 2 |
Two Sigma Investments
New York
|
-$52.3K |
| 3 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$28.9K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$23.5K |
| 5 |
AA
ACT Advisors
Asheville,
North Carolina
|
-$16.8K |
ANTX Hedge Fund Activity: Q4 2025 in Review
37 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in AN2 Therapeutics (ANTX) for Q4 2025, worth a combined $9.88M — down 6% from $10.5M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ANTX positions and 3 closed out — a net gain of 2 holders — while 9 added to existing stakes and 8 trimmed.
The largest buyer was Woodline Partners, opening a new position worth an estimated $170K. The largest seller was Renaissance Technologies, cutting an estimated $54.9K.
- 37 institutional investors held AN2 Therapeutics (ANTX) as of Q4 2025, up from 35 in Q3 2025.
- Funds reported $9.88M of AN2 Therapeutics stock for Q4 2025, down 6% quarter-over-quarter.
- 5 funds opened new AN2 Therapeutics positions in Q4 2025 and 3 closed out, a net change of +2 holders.
- The largest AN2 Therapeutics buyer in Q4 2025 was Woodline Partners, an estimated $170K added.
- The largest AN2 Therapeutics seller in Q4 2025 was Renaissance Technologies, an estimated $54.9K sold.
Based on aggregated 13F filings for Q4 2025.